MIP – Extract of Therapeutic Candidates
Extract of PreviPharma's Therapeutic Candidates
Previ0202
Therapeutic Area
Organ failure
Indications pursued
14
Phase
Pre-clinical
Market potential
Very high
IP
Filed
Previ0213
Therapeutic Area
Severe infections
Indications pursued
4
Phase
Discovery, pre-clinical
Market potential
Very high
IP
In prep.
Previ0214
Therapeutic Area
Chronic inflammation (Neurology)
Indications pursued
6
Phase
Discovery
Market potential
High
IP
Filed
Previ0230
Therapeutic Area
Pedriatric infections
Indications pursued
3
Phase
Discovery
Market potential
High
IP
In prep.
Previ0236
Therapeutic Area
Bone metabolism
Indications pursued
1
Phase
Discovery
Market potential
Medium
IP
In prep.
Previ0241
Therapeutic Area
Mulit resistant bacteria
Indications pursued
3
Phase
Discovery
Market potential
Very high
IP
Filed